Table 1.

Characteristics of the dogs in the comparative canine study.

Case ID	Sex*	Breed	Age (years)	Body weight (kg)	Tumor type†	Grade‡	Location	Longest diameter§ (mm)	Previous treatment∥	Number of C. novyi-NT treatment cycles¶
01-R02	FN	Border Collie	14.3	21.7	STS—PNST	II	Left flank	43	None	4
04-R01	MN	Golden Retriever	7.9	34.0	STS—PNST	II	Right maxilla	15	Surgical	4
04-R02	MI	Golden Retriever	12.0	38.8	STS—PNST	I	Right lateral metacarpus	46	Surgical	4
04-R03	MN	Boxer	9.6	29.4	STS—PNST	I	Left medial antebrachium	56	None	3TR
04-R04	FN	St. Bernard	11.7	31.0	OSAc	III	Right proximal humerus	ND	Surgical	1AE
04-R05	MN	Shetland Sheepdog	14.0	13.4	STS—RMS	III	Right cranial antebrachium	45	Surgical and C. novyi-NT spores IV	4
04-R06	FN	Labrador Retriever	11.6	24.3	MCT	III	Right hindlimb digit	23	None	4
04-R08	FN	Shepherd	7.2	28.9	STS—PNST	I	Right medial hindlimb paw	65	Surgical	3PD
10-R01	MN	Golden Retriever	13.7	33.6	OMM	III	Left mandible	27	Surgical	2AE
10-R02	MN	Pit Bull Terrier	10.0	43.6	STS—PNST	I	Right flank	53	Surgical	4
11-R01	MN	Maltese	11.1	8.1	STS—PNST	II	Left pinna	28	Surgical	1TR
11-R02	FN	Labrador Retriever	12.2	30.3	STS—PNST	II	Left stifle	43	None	3IV
11-R04	MN	Husky	10.3	44.3	STS—FBS	I	Right forelimb paw	29	None	4
16-R02	MN	Labrador Retriever	9.8	36.8	STS—MXS	I	Left lateral thigh	91	Surgical	4
16-R03	FN	Shepherd	10.8	20.8	STS—SCS	I	Left forelimb paw	53	Surgical	4
26-R01	MN	Labrador Retriever	7.9	30.8	STS—RMS	II	Right forelimb paw	24	None	4

^*FN, female neutered; MN, male neutered; MI, male intact.

^†STS, soft tissue sarcoma; PNST, peripheral nerve sheath tumor; OSAc, chondroblastic osteosarcoma; RMS, rhabdomyosarcoma; MCT, mast cell tumor; OMM, oral malignant melamona; FBS, fibrosarcoma; MXS, myxosarcoma; SCS, synovial cell sarcoma.

^‡Grading based on published criteria (43–46): I, low grade; II, intermediate grade; III, high grade; NA, not assessed.

^§Longest diameter at time of first C. novyi-NT injection (day 0). ND, unmeasurable because of location.

^∥04-R05, previous C. novyi-NT therapy with a single intravenous injection of 1 × 10⁷ spores/m² 437 days before the first intratumoral injection of C. novyi-NT spores.

^¶A treatment cycle consisted of one intratumoral injection of 1 × 10⁸ C. novyi-NT spores. Dogs received up to four cycles, typically 1 week apart. Reason for receiving fewer than four treatment cycles given in superscript: TR, tumor response; AE, adverse event; PD, progressive disease; IV, fourth dose given intravenously.